Cargando…

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

Mostrar otras versiones (1)

The single-agent activity of rapalogs (rapamycin and its analogues) in most tumor types has been modest at best. The underlying mechanisms are largely unclear. In this report, we have uncovered a critical role of GSK3 in regulating degradation of some oncogenic proteins induced by rapalogs and cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koo, Junghui, Wang, Xuerong, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496196/ https://www.ncbi.nlm.nih.gov/pubmed/25797247

Ejemplares similares

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis
por: Ren, Hui, et al.
Publicado: (2013)

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Xu, Cheng-Xiong, et al.
Publicado: (2011)

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing
por: Oh, You-Take, et al.
Publicado: (2015)

Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
por: Behera, Madhusmita, et al.
Publicado: (2011)

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
por: Chen, Zhengjia, et al.
Publicado: (2013)

Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells
por: Li, Shaohua, et al.
Publicado: (2015)

From rapalogs to anti-aging formula
por: Blagosklonny, Mikhail V.
Publicado: (2017)

Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
por: Blagosklonny, Mikhail V.
Publicado: (2012)

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models
por: Owonikoko, Taofeek K., et al.
Publicado: (2019)

Small Molecule Bax Agonists for Cancer Therapy
por: Xin, Meiguo, et al.
Publicado: (2014)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury
por: Petrache, Irina, et al.
Publicado: (2021)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells
por: Webber, Philip J., et al.
Publicado: (2015)

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
por: Owonikoko, Taofeek K., et al.
Publicado: (2016)

Oncogenic role of EAPII in lung cancer development and its activation of the MAPK–ERK pathway
por: Li, C, et al.
Publicado: (2011)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells
por: Valianou, Matthildi, et al.
Publicado: (2019)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2
por: Shi, Guoli, et al.
Publicado: (2022)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

In Lebanon “It Never Rains But It Pours”—How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises
por: Khuri, Fadlo R.
Publicado: (2021)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor
por: Huang, Lei, et al.
Publicado: (2021)

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
por: Harvey, R. Donald, et al.
Publicado: (2020)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

Detection of Rapalog-Mediated Therapeutic Response in Renal Cancer Xenografts Using (64)Cu-bevacizumab ImmunoPET
por: Chang, Albert J., et al.
Publicado: (2013)

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
por: Watari, Kosuke, et al.
Publicado: (2016)

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner
por: Posada, Itziar M.D., et al.
Publicado: (2017)

The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19
por: Bischof, Evelyne, et al.
Publicado: (2021)

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
por: Zhang, Shuo, et al.
Publicado: (2021)

Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
por: Dudgeon, Crissy, et al.
Publicado: (2012)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589
por: Kauh, John, et al.
Publicado: (2010)

A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides
por: Du, Yuhong, et al.
Publicado: (2008)

Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs
por: Li, Zijian, et al.
Publicado: (2014)

Discovery of Small Molecule Bak Activator for Lung Cancer Therapy
por: Park, Dongkyoo, et al.
Publicado: (2021)

Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth
por: Wang, Xiaohong, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_eo8av09oskpg0fmq84ah7cisj1